Euangelion — original explanatory figure
Created 9 October 2026, America/Los_Angeles.
Original paper SVG composition and responsive data.
Original Euangelion composition from cited facts; no third-party image, artwork or layout reproduced.
Source basis: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-combination-chemotherapy-stage-iii-mismatch-repair-deficient-colon-cancer
Original factual source/check timestamps are unchanged by this stylistic revision.
Different endpoints and populations; these outcomes cannot be subtracted into a net benefit or treated as an overall-survival result.
Two distinct zero-based percentage comparisons preserve endpoints and populations. Three-year disease-free survival: immunotherapy plus chemotherapy 86.3 percent, randomized n=355, with reported 95 percent confidence interval 81.8–89.8; chemotherapy 76.2 percent, randomized n=357, with 95 percent interval 70.9–80.6. Grade 3/4 adverse events: 84.1 percent, treated safety n=346, versus 71.9 percent, n=334. No adverse-event bounds are supplied. These are different outcomes and cannot be subtracted into a net benefit or treated as an overall-survival result.